Sibylla Biotech Revenue
Biotechnology Research • 
Bresso, Lombardy, Italy • 21-50 Employees
Sibylla Biotech revenue & valuation
| Annual revenue | $4,111,111 |
| Revenue per employee | $98,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $13,200,000 |
| Total funding | $23,000,000 |
Key Contacts at Sibylla Biotech
Giovanni Rizzo
Member Board Of Directors
Lidia Pieri
Chief Executive Officer
Giovanni Spagnolli
Chief Technology Officer
Company overview
| Headquarters | Via Lillo del Duca 10, Bresso, MI 20091, IT |
| Phone number | +3904514620238 |
| Website | |
| NAICS | 541714 |
| Employees | 21-50 |
| Socials |
Sibylla Biotech Email Formats
Sibylla Biotech uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@sibyllabiotech.it), used 68.8% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@sibyllabiotech.it | 68.8% |
{first initial}.{last name} | j.doe@sibyllabiotech.it | 31.2% |
About Sibylla Biotech
Sibylla is an innovative start-up founded in 2017 as a spin-OFF of the INFN (National Institute of Nuclear Physics) and the Trento and Perugia Universities. Its multidisciplinary team of co-founders has developed a pioneering Early Drug Discovery method that applies to the research and design of new drugs, effective against diseases so far incurable. Drug discovery is an extremely complex problem, therefore requiring innovation. Sibylla is a beautiful example of how innovation can be pushed forward by a multidisciplinary and agile team. Sibylla's approach is based on the possibility of simulating the folding pathway from the amino acid sequence as produced by the cells' ribosomes to the native state. Traditional pharmacological methods investigate the target proteins' interaction sites in their native, biologically active state. Novel methods act at the DNA level. Sibylla follows an alternative approach. We identify small molecules that bind to pockets found in the intermediate folding state. These pockets disappear in the native state, and that is why we may try to drug proteins which have been so far considered undruggable. Sibylla technology is called PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting). A molecule found through PPI-FIT would impair the folding of the protein, leading it to degradation. The overall effect is a selective reduction of the expression level of the target protein. The medical areas focused on by Sibylla's research include oncology and antibiotic resistance, although the technology can be applied to any therapeutic area. The company is developing a proprietary pipeline of potential drugs. We can also provide co-development or identifying potential drugs for pharmaceutical companies' specific targets. We recently signed a collaboration agreement with an important Pharma company. Besides the promising results already achieved, Sibylla keeps being engaged in developing proprietary computing technology.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Sibylla Biotech has 18 employees across 6 departments.
Departments
Number of employees
Sibylla Biotech Tech Stack
Discover the technologies and tools that power Sibylla Biotech's digital infrastructure, from frameworks to analytics platforms.
Security
Cookie compliance
Mobile frameworks
JavaScript libraries
JavaScript libraries
Webmail
Miscellaneous
Programming languages
Blogs
Page builders
Analytics
SEO
United Kingdom
New Zealand
United States
Taiwan, Province of China
BrazilFrequently asked questions
4.8
40,000 users
